Answers are grounded in this paper and cite their sources.
Identification of molecular therapy impacts on immunopeptidome in DMG, suggesting improved treatment strategies.
MTX-241F changes the glioma immunopeptidome, unveiling H2B1K, brain-enriched, and treatment-induced immunopeptides as immunologically visible targets. These findings provide a rationale for integrating molecularly targeted therapy with immunotherapeutic approaches to enhance tumor recognition and treatment efficacy in DMG and GBM.
No takes yet. Share an insight, caveat, or question.
Khairkhah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: